PRAX
PRAXIS PRECISION MEDICINES I
About PRAX
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. It is focused on translating genetic insights into the development of therapies for central nervous system (CNS) disorders. Its portfolio of CNS programs is structured by therapeutic focus in three primary franchises, which include Psychiatry, Movement Disorders, and Epilepsy. It has three product candidates, which include PRAX-114, PRAX-944 and PRAX-562. PRAX-114 is an extra synaptic gamma-aminobutyric acid-A (GABAA) receptor preferring positive allosteric modulator (PAM) for the treatment of a range of patients suffering from major depressive disorder (MDD) and perimenopausal depression (PMD). PRAX-944 is a differentiated selective small molecule inhibitor of T-type calcium channels developed for the treatment of Essential Tremor (ET) and Parkinson's Disease(PD). PRAX-114 is developed for the treatment of a range of patients suffering from post-traumatic stress disorder (PTSD).
Buy US stocks in Australia starting with PRAX. Open an account and start investing today!
$212.50M
-
0.00%
466
$4.83
$4.46
$0.00
$15.32
$1.48
PRAX FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in PRAX
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
